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Aims: Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of IDeg and
IAsp. This pan-Asian, 26-week trial investigated efficacy and safety of IDegAsp vs biphasic
insulin aspart 30 (BIAsp 30) in Asian adults with type 2 diabetes (T2DM), inadequately
controlled on once- or twice-daily (BID) basal, premixed or self-mixed insulin.
Methods: Participants (mean age 59.8 years, HbA1c 8.4%, FPG 7.9 mmol/L, BMI 25.4 kg/m
2)
were randomised 2:1 to BID IDegAsp (n = 282) or BIAsp 30 (n = 142) and continued existing
metformin treatment. Insulins were administered with breakfast and main evening meal,
titrated to a pre-breakfast and pre-main evening meal self-measured plasma glucose target
of 4–5 mmol/L.
Results: IDegAsp achieved the primary endpoint of non-inferiority to BIAsp 30 for mean
change in HbA1c (estimated treatment difference [ETD] IDegAsp–BIAsp 30: 0.05% points [95%
CI 0.10; 0.20]). IDegAsp was superior in lowering fasting plasma glucose (FPG) (ETD
1.06 mmol/L, 95% CI 1.43; 0.70, p < 0.001), and resulted in a lower final mean daily
insulin dose (0.79 U/kg vs 0.99 U/kg, estimated rate ratio [RR] 0.79, 95% CI 0.73; 0.85,
p < 0.0001).
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Rates of overall confirmed and severe hypoglycaemia were similar between treatments,
while rate of nocturnal confirmed hypoglycaemia was numerically ( p = ns) lower with
IDegAsp. During the maintenance period there was a trend ( p = ns) towards lower hypo-
glycaemia rates for IDegAsp.
Conclusion: In Asian adults with T2DM, IDegAsp BID effectively improves long-term
glycaemic control, and compared to BIAsp 30, provides superior reductions in FPG with a
lower dose, and numerically less nocturnal hypoglycaemia.
# 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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The characteristics of type 2 diabetes mellitus (T2DM) differ
between Caucasian and Asian patients, with the latter
typically demonstrating a younger age of onset at lower BMI
levels [1]. Elevated glycated haemoglobin (HbA1c) levels have
been shown to be associated with substantial reductions in
insulin secretion in Asian subjects [2]. This may explain why
additional prandial control is often a treatment consideration
in Asian subjects with T2DM [3], with premix insulin regimens
seen as a more convenient option compared to basal and bolus
regimens for patients in clinical practice. In addition, evidence
exists to suggest that race and ethnicity may account for
variations in drug responsiveness [4]. Indeed, different racial
groups have been found to respond differently to insulin
treatment depending on insulin type and intensity [5]. These
differences in patient characteristics are reflected in the
choices of insulin regimen for initiation and intensification;
premixed insulin is the most commonly prescribed insulin in
South Asia and China, while basal insulin is more frequently
used in the USA [6].
Insulin degludec (IDeg) is a novel basal insulin analogue
with ultra-long duration of action that forms soluble multi-
hexamers upon subcutaneous injection, resulting in 25 h
half-life and a flat and stable glucose-lowering effect at steady
state [7] with four-times less pharmacodynamic variability
than insulin glargine (IGlar) [8]. These characteristics translate
into lower rates of hypoglycaemia (especially nocturnal
episodes) compared to IGlar in patients with T2DM [9], and
the potential for flexible dosing times to accommodate varying
lifestyles [10].
Insulin degludec can be co-formulated with the rapid-
acting analogue insulin aspart (IAsp), resulting in the soluble
co-formulation insulin degludec/insulin aspart (IDegAsp: 70%
v/v IDeg as basal insulin and 30% v/v IAsp as prandial insulin).
This provides both mealtime coverage and full 24-hour basal
coverage in a single injection [11].
Premixed insulins are a common approach when initiating
insulin therapy for T2DM in Asian countries. Several studies
have compared the safety and efficacy of IDegAsp with other
insulin treatments in insulin-naive Asian patients with T2DM.
A global proof-of-concept study in insulin-naive patients with
T2DM reported that treatment with IDegAsp achieved com-
parable HbA1c levels with significant reductions in both fasting
plasma glucose (FPG) and overall hypoglycaemia rate com-
pared with biphasic insulin aspart 30 (BIAsp 30) [12]. In aseparate trial of insulin-naive Japanese patients with T2DM,
IDegAsp administered once-daily with the main meal resulted
in superior HbA1c reduction, similar reductions in FPG and a
numerically lower rate of overall and nocturnal hypoglycae-
mia compared to IGlar alone [13]. In line with these results, a
separate, confirmatory, randomised, controlled 26-week trial
in insulin-experienced subjects demonstrated comparable
HbA1c control for IDegAsp and BIAsp 30 (as expected in a treat-
to-target [TTT] design), with superior reduction in FPG for
IDegAsp [14]. In the same study, total daily insulin dose was
significantly lower for IDegAsp vs BIAsp 30. IDegAsp was also
associated with significantly lower rates of overall and noctur-
nal hypoglycaemia episodes compared to BIAsp 30, with the
difference between treatments being more pronounced during
the maintenance period [14]. Taken together, these results
indicate IDegAsp provides both specific mealtime coverage and
the benefits of full 24-hour basal coverage in a single injection.
However, data regarding the efficacy and safety of IDegAsp
twice daily (BID), specifically in insulin-experienced patients in
the Asian population, are currently lacking.
As a result, this trial was designed to investigate the
efficacy and safety of IDegAsp and BIAsp 30, both adminis-
tered twice-daily in Asian adults with T2DM, inadequately
controlled on basal insulin or pre- or self-mixed insulin,
administered once- or twice-daily, with or without metformin.
2. Materials and methods
2.1. Study design and participants
A total of 45 sites in five countries (Hong Kong, Japan, Malaysia,
South Korea and Taiwan) participated in this 26-week, open-
label, randomised, controlled, stratified, treat-to-target trial.
The protocol, protocol amendments, consent form and subject
information sheet were reviewed and approved by appropriate
authorities according to local regulations, and by local
Institutional Ethics Committees, prior to trial initiation. The
study was carried out in accordance with the Declaration of
Helsinki and Good Clinical Practice Guidelines (World Medical
Association, International Conference on Harmonisation).
Study participants were informed of the risks and benefits
of the trial, and could withdraw from the trial at any time for
any reason. All study participants gave their consent in writing
before any trial-related activities.
Eligible male and female participants were Asian adults
18 years of age (20 years of age for Japan and Taiwan,
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T2DM for 6 months, HbA1c 7.0–10.0% (both inclusive) by
central laboratory analysis and a body mass index
(BMI) 35.0 kg/m2. Study participants had been receiving
once- or twice daily-basal insulin, a premixed insulin or a
self-mixed insulin containing 20–40% fast/rapid-acting com-
ponent, with or without metformin, for at least 3 months prior
to screening.
Patients were excluded if they received treatment with oral
antidiabetic drugs other than metformin within the last 8
weeks prior to study visit, if they received treatment with
thiazolidinediones or glucagon-like peptide 1 receptor ago-
nists within 3 months of study, if they had an anticipated
change in concomitant medication known to interfere
significantly with glucose metabolism, or if they had any
clinically significant disease or disorder (including cardiovas-
cular disease within the previous 6 months, renal or hepatic
impairment, uncontrolled severe hypertension, proliferative
retinopathy or maculopathy requiring treatment, cancer or
medical history of cancer, known or suspected abuse of
alcohol, narcotics or illicit drugs or a history of recurrent
severe hypoglycaemia or hypoglycaemic unawareness) or any
other condition (except for conditions associated with T2DM)
that could, in the investigator’s opinion, interfere with trial
results.
2.2. Study procedures
Prior to randomisation, eligible patients discontinued their
diabetes treatment except for metformin, and were switched
from their prior insulin treatment to IDegAsp or BIAsp 30.
Stratification was performed according to previous insulin
regimen and metformin treatment at screening. Patients
were randomised (2:1) to twice daily injections of IDegAsp
(70% IDeg and 30% IAsp; Novo Nordisk A/S, Bagsværd,
Denmark; 100 U/mL) or BIAsp 30 (NovoMix 301, Novo Nordisk
A/S; 100 U/mL), both with or without metformin, for 26
weeks. This unequal randomisation was to be performed in
order to ensure an adequate number of subjects were
exposed to IDegAsp across the entire clinical program for
subsequent secondary analyses. The trial design could not be
blinded and was therefore open-label, since in contrast to
IDegAsp, BIAsp 30 requires re-suspension prior to injection.
Patients were switched to biphasic human insulin 30 at the
last treatment visit (Week 26) until the follow-up visit (Week
28). The rationale for the switch is that biphasic human
insulin 30 is a human insulin and consequently possible
interference with antibody measurements was reduced at
the follow-up visit.
Patients who had previously been receiving once-daily
basal or premixed/self-mixed insulin were started on twice-
daily doses of trial insulin by splitting the total dose of
previous non-trial insulin treatment into two equal doses of
trial insulin: one administered with the breakfast meal and the
other with the main evening meal. Patients receiving twice-
daily basal or premixed insulin were recommended to transfer
their pre-breakfast and pre-main evening meal dose unit-to-
unit to trial insulin. Patients receiving a self-mixed regimen
transferred to trial insulin at doses corresponding to their
respective self-mixed pre-meal dose.The dose of both trial insulins was titrated according to a
pre-breakfast and pre-main evening meal self-measured
plasma glucose (SMPG) target of 4 to < 5 mmol/L (72 to
< 90 mg/dL). For increasing the insulin dose, the titration was
based on the mean pre-breakfast SMPG and the mean pre-
main evening meal SMPG from the preceding 3 days. Titration
of pre-main evening meal insulin dose was based on the
patients’ mean pre-breakfast glucose values and titration of
pre-breakfast insulin dose was based on the mean pre-main
evening meal glucose values (Supplementary Table 1). Insulin
dose was reduced if the single pre-breakfast/pre-main evening
dose was <3.9 mmol/L (70 mg/dL) for no obvious reason
(Supplementary Table 1).
2.3. Assessments
The primary endpoint was the change from baseline in HbA1c
after 26 weeks of treatment. Secondary endpoints included the
proportion of patients achieving HbA1c < 7.0% or 6.5% at the
end of the trial; the proportion reaching these targets in the
absence of confirmed hypoglycaemia during the last 12 weeks
of treatment (confirmed by a plasma glucose [PG] measure-
ment of <3.1 mmol/L [56 mg/dL] regardless of symptoms or if
classified as severe); and change from baseline in body weight.
Other secondary efficacy endpoints included the change from
baseline in FPG and in the 9-point SMPG profiles.
Safety assessments included adverse events (AEs), hypo-
glycaemic episodes, insulin dose, body weight, vital signs,
physical examination, fundoscopy/fundusphotography, elec-
trocardiogram (ECG), standard biochemical and haematology
measures, and insulin antibodies (IDeg-specific, IAsp-specific
and antibodies cross-reacting between IDeg and IAsp and
between IDeg and human insulin). Laboratory analyses were
performed by Quintiles East Asia Pte. Ltd (Singapore Science
Park 1, Singapore), Medca Japan Company Ltd (Konsu-shi,
Japan) and Quintiles Laboratories Japan (Tokyo, Japan).
Antibodies specific to IDeg and cross-reacting between IDeg
and human insulin were analysed by Celerion (Fehraltorf,
Switzerland) using a validated subtraction radioimmunoassay
method [15,16]. Confirmed hypoglycaemia episodes were
either those classified as severe according to American
Diabetes Association (ADA) criteria (as per ADA classification
[17,18] or verified by a plasma glucose measurement of
<3.1 mmol/L (56 mg/dL), regardless of symptoms. Hypogly-
caemia was classified as nocturnal if the time of onset was
from 00.01 to 05.59 h.
Patient-reported outcomes were assessed by a series of
four questionnaires: Diabetes Medication Satisfaction Ques-
tionnaire (DiabMedSat); Diabetes Productivity Measure (DPM);
Treatment Related Impact Measure-Diabetes (TRIM-D); Short-
Form 36 Health Survey version 2 (SF-36 v2).
2.4. Statistical methods
The primary objective of this trial was to demonstrate non-
inferiority of IDegAsp to BIAsp 30, (non-inferiority limit of
0.4%) as assessed by the change in HbA1c from baseline after 26
weeks. The primary efficacy endpoint of change from baseline
in HbA1c after 26 weeks of treatment was analysed using an
analysis of variance (ANOVA) with treatment, antidiabetic
Fig. 1 – Trial flow diagram. *Non-compliance with protocol-
specified dosing of drug; yOther, violation of inclusion/
exclusion criteria, withdrawal of informed consent, lost to
follow-up, and other reasons
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and baseline HbA1c as covariates.
Secondary endpoints included the proportion of HbA1c
responders and non-responders based on whether the
patients met the ADA HbA1c target of <7.0% [18] and the
International Diabetes Federation HbA1c target of <6.5% [19].
These were analysed separately based on a logistic regression
model using treatment, antidiabetic therapy at screening, sex
and region as fixed factors and age and baseline HbA1c as
covariates. Additional endpoints including the change from
baseline in FPG, mean SMPG and body weight, were analysed
using an ANOVA method with treatment, antidiabetic therapy
at screening, sex and region as fixed factors and age and
baseline FPG as covariates. In a post hoc analysis, mean total
daily insulin dose, morning and afternoon doses after a 26-
week treatment were analysed using a similar ANOVA
method.
From the mean before-meal PG value a dichotomous
endpoint (responder/non-responder) was derived showing if
a subject had achieved the titration target at each time point.
Survival endpoints were derived describing the time from
randomisation to the date a subject met the titration target for
the first time, and the time until a subject met the titration
target and stayed on target for the remaining treatment
period. Survival endpoints were analysed separately in a Cox
proportional hazards model including treatment, antidiabetic
therapy at screening, sex and region as fixed factors and age as
covariate. An analysis was also performed for the time until all
titration targets were met.
The number of hypoglycaemic episodes was analysed
using a negative binomial regression model with a log-link
function and the logarithm of the time period in which a
hypoglycaemic episode was considered treatment emergent
as offset. The model included treatment, antidiabetic therapy
at screening, sex and region as fixed factors, age as a covariate
and exposure as offset. In cases where there were a small
number of episodes and where the negative binomial
regression analysis did not converge, a Poisson regression
model was used for post hoc analyses. This was done to
calculate the estimated rate ratio (RR) for severe hypoglycae-
mia between the two treatment groups. Furthermore, a post
hoc analysis, using the same methodology, was performed in
order to examine hypoglycaemia rates during the mainte-
nance period, once glycaemic control and insulin dose had
been stabilised. The maintenance period (16 weeks onwards)
was deliberately selected to be comparable to an earlier pre-
planned meta-analysis of all IDeg phase III clinical trials
versus IGlar [9].
Other AEs were analysed using descriptive statistics.
3. Results
3.1. Patients
Of the 594 patients enrolled in the study, 424 patients were
randomised to receive either IDegAsp or BIAsp 30. The 170
patients withdrawn prior to treatment exposure did not fulfil
the inclusion criteria, withdrew consent or had a protocol
violation (Fig. 1). Baseline characteristics including level ofglycaemic control, duration of diabetes and body mass index
were generally comparable between the two treatment groups
(Table 1). The IDegAsp group had 29% of patients >65 years of
age, while the BIAsp 30 group had 39% in this category. Most
patients were of Asian non-Indian race, mainly from Japan
and South Korea. Overall, 29.3% and 29.6% of patients were on
basal insulin with or without metformin for IDegAsp and
BIAsp 30, respectively. A total of 70.7% and 70.4% of patients
were on premix/self-mix insulin with or without metformin
for IDegAsp and BIAsp 30, respectively (Table 1).
3.2. Glycaemic control
Mean HbA1c profiles were similar between treatment groups.
After 26 weeks of treatment, mean (standard deviation [SD])
HbA1c decreased from 8.4  0.8% at baseline to 7.1  0.8% for
IDegAsp and from 8.4  0.9% at baseline to 7.0  0.8% for BIAsp
30 (Fig. 2). Both groups showed similar decreases in HbA1c
profiles from baseline to end of trial; 1.38% points for
IDegAsp and 1.42% points for BIAsp 30. The mean estimated
treatment difference (ETD) between IDegAsp and BIAsp 30 was
0.05% points (95% confidence interval [CI] 0.10; 0.20),
demonstrating that IDegAsp BID was non-inferior to BIAsp
30 BID in lowering HbA1c, as expected in a TTT design.
The proportion of patients achieving HbA1c targets of <7.0%
at the end of the trial was comparable, 48.2% vs 49.3% for
IDegAsp and BIAsp 30, respectively (odds ratio [OR] IDegAsp/
BIAsp 30: 0.94, 95% CI 0.61; 1.44). Similarly, the proportion of
patients achieving HbA1c  6.5% was 28.9% with IDegAsp and
27.5% with BIAsp 30 (OR IDegAsp/BIAsp 30: 1.06, 95% CI 0.66;
1.70).
Table 1 – Baseline characteristics of randomised popu-
lation.
Characteristic IDegAsp
(n = 280*)
BIAsp 30
(n = 142)
Sex male/female, % 54/46 56/44
Asian Indian, n (%) 12 (4.3) 7 (4.9)
Asian non-Indian, n (%) 267 (95.7) 135 (95.1)
Mean age, years (SD) 59.1 (10.2) 61.2 (9.5)
Weight, kg (SD) 66.1 (11.2) 66.0 (11.2)
BMI, kg/m2 (SD) 25.4 (3.4) 25.4 (3.7)
Duration of diabetes, years (SD) 16.3 (7.9) 16.3 (8.2)
HbA1c, % (SD) 8.4 (0.8) 8.4 (0.9)
FPG, mmol/L (SD) 7.9 (2.5) 7.9 (2.5)
Pre-study antidiabetic regimen
Basal insulin, n (%)
Basal insulin + metformin, n (%)
Premix or self-mix, n (%)
Premix or self-mix + metformin, n (%)
31 (11.1)
51 (18.2)
81 (28.9)
117 (41.8)
13 (9.2)
29 (20.4)
44 (31.0)
56 (39.4)
SD, standard deviation; FPG, fasting plasma glucose.
* Two subjects in the IDegAsp group were randomised in error in
spite of being screening failures and were subsequently excluded
from the full analysis set.
Fig. 3 – Mean FPG over time for IDegAsp and BIAsp 30 BID.
Error bars depict W SEM
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confirmed hypoglycaemia in the last 12 weeks was 21.9% with
IDegAsp and 13.2% with BIAsp 30. The odds of achieving this
target were numerically higher (77%) with IDegAsp compared to
BIAsp 30, (OR IDegAsp/BIAsp 30: 1.77, 95% CI 0.97; 3.25, p = ns).
The proportions of patients who achieved HbA1c  6.5% without
confirmed hypoglycaemia in the last 12 weeks were 12.1% and
10.1% with IDegAsp and BIAsp 30, respectively (OR IDegAsp/
BIAsp 30: 1.18, 95% CI 0.58; 2.38, p = ns).
After 26 weeks of treatment, observed mean (SD) FPG
decreased from 7.9  2.5 mmol/L at baseline to
5.4  1.8 mmol/L with IDegAsp and from 7.9  2.5 mmol/L at
baseline to 6.5  1.9 mmol/L with BIAsp 30 (Fig. 3). IDegAsp
achieved superiority to BIAsp 30 in lowering FPG (ETD -
1.06 mmol/L (95% CI -1.43; -0.70; p < 0.001).
Overall, the mean 9-point SMPG profiles were similar
between IDegAsp and BIAsp 30 at baseline. After 26 weeks of
treatment, the estimated means of the 9-point SMPG profiles
were 7.6 mmol/L and 7.9 mmol/L for patients treated with
IDegAsp and BIAsp 30, respectively (ETD -0.19, 95% CI 0.54;
0.16) (Fig. 4). Estimated mean SMPG levels were significantlyFig. 2 – Mean HbA1c over time for IDegAsp and BIAsp 30
BID. Error Bars depict W SEM, in some cases these were too
small to represent graphicallylower (as 95% CIs did not include 0) for IDegAsp than for BIAsp
30 before breakfast, 90 min after breakfast, at 4.00 h and before
breakfast the following day, corresponding to ETD of
0.84 mmol/L (95% CI 1.21; 0.46), 0.81 mmol/L (95% CI
1.44; 0.18), 0.46 mmol/L (95% CI 0.91; 0.00) and
0.89 mmol/L (95% CI 1.26; -0.53), respectively. In contrast,
the SMPG values at bedtime were significantly higher for
IDegAsp compared to BIAsp 30 (ETD 0.93 mmol/L 95% CI 0.31;
1.56) (Fig. 4).
At baseline the mean change in nocturnal PG (bedtime to
breakfast) was similar between IDegAsp (2.8 mmol/L) and
BIAsp 30 (2.9 mmol/L). At Week 26 the mean change in
nocturnal PG was 3.1 mmol/L with IDegAsp and 1.3 mmol/L
with BIAsp 30 (ETD 1.89 mmol/L 95% CI 2.49; 1.28). The
greater decrease in nocturnal PG observed with IDegAsp than
with BIAsp 30 was mainly due to the significantly greater PG
decrease from bedtime to 04.00 h (ETD 1.63 mmol/L 95% CI
2.25; 1.02).
During 26 weeks of treatment, a numerically higher ( p = ns)
proportion of patients achieved the pre-breakfast titration
target of <5 mmol/L with IDegAsp than with BIAsp 30 (33.9%
versus 14.2%). These results are supported by the lower pre-
breakfast SMPG values for IDegAsp compared with BIAsp 30.
The proportion of subjects who achieved the pre-main
evening meal target was numerically higher with IDegAsp
(13.6%) compared to BIAsp 30 (8.5%, p = ns).
Moreover, patients treated with IDegAsp reached the pre-
breakfast and pre-evening targets for the first time faster than
patients treated with BIAsp 30 (hazard ratio 2.39, 95% CI 1.58;
3.61). With IDegAsp, the median time to achieve titration
targets for the first time was 5 weeks (pre-breakfast target) and
18 weeks (pre-main evening meal), respectively. For BIAsp 30,
the median time to pre-breakfast target was 21 weeks. Time to
evening meal target was not calculated, as less than half of
subjects on BIAsp 30 reached this target during the trial.
3.3. Insulin dose
At baseline, IDegAsp and BIAsp 30 doses were similar. The
mean total daily insulin dose after 26 weeks of treatment was
0.79 U/kg for IDegAsp and 0.99 U/kg for BIAsp 30 (estimated
rate ratio [RR] 0.79, 95% CI 0.73; 0.85, p < 0.0001). The morning
and afternoon doses after 26 weeks were 34 U and 21 U for
Fig. 4 – 9-point SMPG profile of IDegAsp and BIAsp 30 BID at baseline and at 26 weeks. *Denotes statistically significant
difference between treatments
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and 38 U and 30 U for BIAsp 30 (dose split pre-breakfast:pre-
dinner was 56%:44%), respectively.
3.4. Body weight
Small and similar increases in body weight were observed
from baseline to Week 26 for both treatments. Numerically
smaller increases were seen with IDegAsp (1.30 kg) compared
to BIAsp 30 (1.67 kg) (ETD 0.38 kg, 95% CI 0.96; 0.21, p = ns).Table 2 – Hypoglycaemic episodes in the IDegAsp and BIAsp 
Safety analysis set, e
IDegAsp BID BIAsp 
Participants Episodes Rate Particip
n % PYE n 
Severe 4 1.4 6 0.05 2 
Overall
confirmed
250 73.5 1227 9.6 107 
Nocturnal
confirmed
70 25.0 143 1.1 44 
Patients in safety analysis set with at least 16 weeks of expo
IDegAsp BID BIAsp 3
Participants Episodes Rate Particip
n % PYE n 
Severe 2 0.8 2 0.04 1 
Overall
confirmed
123 49.0 402 8.5 73 
Nocturnal
confirmed
36 14.3 49 1.0 22 
BID, twice daily; PYE, patient year of exposure; CI, confidence interval; N
* Rate ratios are estimated based on a negative binomial regression mo
diabetic therapy at screening as fixed effects, age as covariate and logar3.5. Hypoglycaemic episodes
Confirmed hypoglycaemia was reported for 73.5% and 75.9% of
patients in the IDegAsp and BIAsp 30 treatment arms,
respectively. During the main treatment period, the rate of
overall confirmed hypoglycaemia was similar between IDe-
gAsp and BIAsp 30 with 9.6 episodes/patient/year vs 9.5
episodes/patient/year (RR 1.00, 95% CI 0.76; 1.32, p = ns)
(Table 2). The rate of nocturnal confirmed hypoglycaemia
(confirmed hypoglycaemia with onset at 00.01–05.59 h) was30 groups.
ntire trial period
30 BID Estimated
rate ratio
(95% CI)*
p value
ants Episodes Rate
% PYE IDegAsp/
BIAsp 30
1.4 2 0.03 1.3 (0.24; 7.03) NS
75.8 621 9.5 1.00 (0.76; 1.32) NS
31.2 101 1.6 0.67 (0.43; 1.06) NS
sure, maintenance period (16 weeks to end of treatment)
0 BID Estimated
rate ratio
(95% CI)*
p value
ants Episodes Rate
% PYE IDegAsp/
BIAsp 30
0.8 1 0.04 0.69 (0.05; 9.8) NS
56.6 239 9.8 0.84 (0.6; 1.19) NS
17.1 35 1.4 0.70 (0.39; 1.26) NS
S, not significant.
del using a log-link and with treatment, trial, sex region and anti-
ithm of the exposure time (100 years) as offset.
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compared with BIAsp 30 (1.6 episodes/patient/year; RR 0.67,
95% CI 0.43; 1.06; p = ns). Severe hypoglycaemia was infre-
quent and reported for 1.4% of subjects in IDegAsp and BIAsp
30 groups; the rate of severe hypoglycaemia with IDegAsp and
BIAsp 30 was 0.05 and 0.03 episodes/patient/year, respectively.
Post hoc analyses of severe hypoglycaemia rates showed no
statistically significant difference between the groups (RR 1.3,
95% CI 0.24; 7.03, p = ns) (Table 2).
During the maintenance period there was a trend towards
lower overall confirmed (RR 0.84, 95% CI 0.6; 1.19, p = ns),
severe (RR 0.69, 95% CI 0.05; 9.8, p = ns) and nocturnal
confirmed (RR 0.70, 95% CI 0.39; 1.26, p = ns) hypoglycaemia
rates for IDegAsp compared with BIAsp 30. Nocturnal
confirmed hypoglycaemia rates during the maintenance
period were similar to the full trial period (RR 0.67, 95% CI
0.43; 1.06, p = ns) (Table 2).
3.6. Patient-reported outcomes
Based on the TRIM-D questionnaire, the perceived treatment
burden significantly improved with IDegAsp compared with
BIAsp 30, as the 95% CI did not include 0 (ETD 5.2, 95% CI 1.3;
9.1). The results from the DPM questionnaire showed that
changes in is ‘Life Productivity’ score (ETD 3.8, 95% CI 1.0; 6.7)
and ‘Work Productivity’ score (ETD 5.0, 95% CI 1.4; 8.6) were
significantly in favour of IDegAsp (95% CI did not include 0).
Similarly, the overall mental score, based on the SF-36 v2,
significantly improved with IDegAsp compared with BIAsp 30
(ETD 2.3, 95% CI 0.6; 3.9). The ‘Mental health’ and ‘Role-
emotional’ domain scores significantly improved with IDe-
gAsp (ETD 1.8, 95% CI 0.1; 3.5) compared with BIAsp 30 (ETD 3.1,
95% CI 1.1; 5.1). No statistically significant differences were
found for the other domains and summary score.
3.7. Adverse events
The incidence of AEs was similar between IDegAsp (69.5%) and
BIAsp 30 (73.0%) and the majority of AEs were mild-to-
moderate in severity. The most frequent AEs in both treatment
groups were nasopharyngitis, upper respiratory tract infection
and diabetic retinopathy.
Serious adverse events (SAEs) were reported in 23 (8.2%)
and 12 (8.5%) patients in the IDegAsp and BIAsp 30 treatment
groups, respectively. Three of the patients (two cases of
hypoglycaemic unconsciousness and one case of hypoglycae-
mia) receiving IDegAsp and one of the patients (hypoglycae-
mic unconsciousness) receiving BIAsp 30 were considered to
have AEs possibly or probably related to insulin treatment. The
most frequently reported SAEs were hypoglycaemia and
hypoglycaemic unconsciousness (0.02 events/patient-year)
for IDegAsp and acute myocardial infarction (0.03 events/
patient-year) for BIAsp 30. One death was reported in this trial
attributed to interstitial lung disease in the IDegAsp group and
was considered unlikely to be related to treatment. Patients
who reported other SAEs all recovered completely.
The mean level of insulin antibodies cross-reacting with
human insulin was modest at baseline, decreasing marginally
from baseline with IDegAsp and increasing slightly with BIAsp
30 after 26 weeks of treatment. Throughout the treatmentperiod, the mean level of IDeg specific antibodies was low. The
mean level of IAsp specific antibodies was low at baseline and
remained low through the treatment and was similar in the
IDegAsp and BIAsp 30 groups (data not shown).
The proportion of patients with injection site reactions was
low in both treatment groups (1.4%). There were no clinically
relevant differences observed in physical examination find-
ings, vital signs, standard laboratory analyses (haematology
and biochemistry), fundoscopy/fundusphotography, or elec-
trocardiogram and lipid levels remained generally stable
during the study (data not shown).
4. Discussion
The results of this confirmatory phase III 26-week trial
demonstrated the efficacy and safety of IDegAsp versus BIAsp
30 in Asian adults with T2DM, inadequately controlled on
basal insulin or pre- or self-mixed insulin, administered once-
or twice-daily, with or without metformin. The lower mean
BMI values for patients in the current study compared to those
typically seen for T2DM populations in western countries
highlight the importance of conducting clinical trials in
different ethnic populations.
In the current study, IDegAsp demonstrated comparable
HbA1c control to BIAsp 30, as expected in a TTT trial.
Pharmacodynamic studies have previously demonstrated
that the basal glucose lowering effect of IDeg is preserved
when co-formulated in IDegAsp. Based on these findings,
IDegAsp should deliver improved FPG control compared to
BIAsp 30, due to the more prolonged glucose lowering effect of
the IDeg component compared to the protaminated portion of
IAsp in BIAsp 30. This was confirmed in the current study, as
IDegAsp resulted in superior FPG reductions compared to
BIAsp 30. Similar findings were reported in a recent global
phase III trial of insulin-experienced adults with T2DM
inadequately controlled on pre- or self-mixed insulin, in
which IDegAsp (BID) led to superior FPG control [14]. In the
same trial, IDegAsp was associated with significantly lower
rates of overall and nocturnal hypoglycaemia episodes
compared to BIAsp 30, with the difference between treatments
becoming more pronounced during the maintenance period
[14].
In the current study, the total daily insulin dose across the
study duration was significantly lower for IDegAsp compared
to BIAsp 30, a finding consistent with the results reported in
the above mentioned phase III trial [14]. This could be related
to the glucose lowering profile of IDegAsp, in which the rapid
acting prandial effect is followed by a distinct separate and
stable basal effect (20). BIAsp 30 is a formulation containing
soluble (30%) rapid-acting IAsp and protaminated (70%) IAsp.
In a once-daily regimen, the GIR returns to baseline values 18–
22 h after injection with BIAsp 30 [21]. The suboptimal
distribution of glucose lowering effect of BIAsp 30 compared
to IDegAsp may explain the differences observed in FPG
control.
The stable basal glucose lowering effect of the IDeg
component of IDegAsp could also explain the differences in
hypoglycaemia rates between treatments observed in this
study. This is particularly relevant in light of the fact that the
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but resulted in different dose levels at the end of treatment
(significantly lower with IDegAsp compared to BIAsp 30).
While similar effects on overall confirmed and severe
hypoglycaemic episodes were noted between the two treat-
ments during the total treatment period, there were numeri-
cally fewer episodes of hypoglycaemia during the
maintenance period for IDegAsp. The latter observation is
in line with results from other studies [9;14] and may prove
important over longer treatment periods. The observed trend
( p = ns) for fewer hypoglycaemic episodes in the maintenance
period may be a reflection of the stabilised insulin dose and
glycaemic profile, leading to numerically fewer episodes of
nocturnal hypoglycaemia during this phase. The differences
between the basal components of the insulins studied may
also contribute to reduced rates of hypoglycaemia observed
here. Unlike IDeg, which provides a stable and consistent
glucose-lowering effect with reduced variability, BIAsp 30 is
associated with a lack of sustained and stable glucose infusion
rate profile [20]. Interestingly, in the global phase III study [14],
the difference in hypoglycaemia between treatments was
more pronounced, as IDegAsp showed significantly lower
rates of overall hypoglycaemia compared to BIAsp 30. When
comparing overall hypoglycaemia rates between the current
study and the global study, the rates for IDegAsp appear
comparable between trials (9.6 vs 9.7 episodes per patient-
year) [14]. By comparison, the rates for BIAsp 30 appear
markedly different in the current study as compared to the
global study (9.5 vs 14.0 episodes per patient-year, respective-
ly) [14]. This difference could be a reflection of the differing
populations and healthcare environments under investiga-
tion. Premixed insulin is more common in Asia [6], and so both
patients and physicians may be more experienced in
administering it in an optimal manner.
In this study no unexpected safety issues were identified
with IDegAsp; there was no apparent difference between
IDegAsp and BIAsp 30 with respect to AEs and standard safety
parameters. Furthermore, antibody development was modest
and only a few injection site reactions are reported with
IDegAsp. The safety profile reported in this study is in line with
findings in previous IDegAsp clinical trials [12–14].
The strengths of the current study include the multicentre,
multinational design, as well as the number of patients who
participated. These aspects allow meaningful conclusions to
be made specifically about the treatment of T2DM in Asian
patients. However, there are some limitations associated with
the current trial design. Due to the differences in appearance
between formulations (IDegAsp is a clear solution whereas
BIAsp 30 is cloudy), this trial was by necessity open label, and
as a result the possibility of bias cannot be completely
excluded. Furthermore, the present trial consisted of 26 weeks
of treatment. Studies of a longer duration would be required to
confirm differences in the longer-term benefits of each
treatment, particularly considering the trends toward lower
rates of hypoglycaemia in the maintenance period of
treatment in favour of IDegAsp.
In conclusion, in Asian patients with T2DM, IDegAsp offers
comparable HbA1c control to BIAsp 30 with superior FPG
control at lower insulin dose, similar rates of overall confirmed
and severe hypoglycaemia and a numerically lower rate ofnocturnal confirmed hypoglycaemia during the main treat-
ment period. In addition, a trend towards lower rates of overall
confirmed, severe and nocturnal confirmed hypoglycaemia
rates during the maintenance period of treatment was also
observed. These findings indicate IDegAsp offers the benefits
of IDeg, such as improved and stable FPG control, full 24-hour
basal coverage, combined with the additional prandial control
required more often in Asian populations.
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